Skip to main content
    Q

    Qualigen Therapeutics Inc (QLGN)

    BIOTECHNOLOGY

    $0.76
    -0.02 (-2.80%)

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Qualigen Therapeutics Inc (QLGN) Financials: Revenue, Profit and Cash Flow

    Updated Sep 30, 2025. Financial statements from company filings, amounts in US dollars.

    Qualigen Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2024, down 100.0% from the year before. That year, net income was -$6.16M, operating cash flow was -$6.33M and free cash flow was -$6.33M. The quarter ended Sep 30, 2025 had revenue of $0 and net income of -$2.04M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $5.76M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$5.20M+4.4%-0.1%-217.2%-257.8%
    Dec 2022$4.98M-11.9%13.7%-360.0%-422.1%
    Dec 2021$5.65M+31.3%23.4%-400.9%-316.6%
    Dec 2020$4.31M-22.5%-66.9%-262.5%-474.2%
    Dec 2019$5.56M-4.2%28.4%-27.0%-32.2%
    Dec 2018$5.80M-40.6%-292.9%-582.2%-290.7%
    Dec 2017$9.78MN/A-80.8%-159.1%-80.4%
    Dec 2016N/AN/AN/AN/AN/A
    Dec 2015N/AN/AN/AN/AN/A
    Annual, fiscal years ended Dec 2015 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss narrowed from the year before. In the quarter ended Sep 2025, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Revenue$0$5.20M$4.98M$5.65M$4.31M$5.56M$5.80M$9.78MN/AN/A
    Cost of revenueN/A$5.21M$4.30M$4.33M$7.19M$3.98M$17.00M$7.90M$18.45M$8.91M
    Gross profitN/A-$4.50K$680.80K$1.32M-$2.88M$1.58M-$17.00M-$7.90M-$18.45M-$8.91M
    Research and development$1.20M$5.21M$6.84M$11.72M$3.55M$1.21M$11.37M$2.87M$13.29M$2.26M
    Operating income-$5.76M-$11.30M-$17.94M-$22.66M-$11.30M-$1.50M-$33.79M-$15.55M-$36.62M-$17.57M
    Net income-$6.16M-$13.42M-$21.03M-$17.90M-$20.42M-$1.79M-$16.87M-$7.86M-$18.38M-$9.18M
    EBITDA-$5.24M-$11.30M-$13.84M-$22.66M-$11.16MN/A-$33.78M-$15.55M-$36.62M-$17.57M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$0$0$2.24M$0$0$0$0$0$7.94M$1.63M$1.61M$1.39M
    Gross profitN/AN/A$1.12MN/A-$123.43K-$754.29K-$364.38K-$4.50K$2.35M$610.49K$342.34K$293.73K
    Operating income-$1.43M-$1.68M-$1.33M-$973.04K-$1.27M-$1.74M-$1.41M-$2.27M-$2.78M-$3.55M-$3.69M-$4.41M
    Net income-$2.04M-$1.69M-$855.82K-$855.82K-$1.79M-$1.58M-$2.03M-$2.47M-$3.66M-$3.46M-$4.11M-$6.37M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents of $1.17M were 24.9% of total assets of $4.69M, against total liabilities of $2.01M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Total assets$4.69M$2.03M$19.08M$22.84M$29.13M$2.80M$15.32M$22.83M$7.24M$16.04M
    Current assets$4.68M$1.17M$10.82M$20.80M$28.22M$2.21M$15.28M$22.80M$7.20M$16.01M
    Cash and equivalents$1.17M$401.80K$7.03M$17.54M$23.98M$1.70M$7.81M$22.63M$7.05M$15.82M
    Total liabilities$2.01M$4.14M$10.32M$6.27M$10.83M$1.70M$5.93M$2.71M$3.13M$1.35M
    Short-term debtN/AN/AN/AN/AN/A$100.47KN/AN/AN/AN/A
    Long-term debtN/AN/AN/AN/AN/A$305.81KN/AN/AN/AN/A
    Shareholder equity$2.68M-$2.10M$7.24M$16.56M$18.29M$1.10M$9.39M$20.13M$4.10M$14.68M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$43.47M$3.96M$4.69M$4.69M$2.31M$534.41K$1.00M$2.03M$4.32M$13.15M$15.91M$19.08M
    Total liabilities$4.92M$5.61M$2.01M$2.01M$4.45M$4.81M$4.52M$4.14M$5.96M$9.84M$9.71M$10.32M
    Cash and equivalents$38.78M$331.60K$1.17M$1.17M$388.15K$118.69K$543.22K$401.80K$2.07M$1.34M$4.36M$7.03M
    Shareholder equity$38.55M-$1.65M$2.68M$2.68M-$2.14M-$4.28M-$3.52M-$2.10M-$1.64M$2.03M$4.87M$7.24M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016Dec 2015
    Operating cash flow-$6.33M-$10.30M-$13.25M-$14.73M-$9.76M$57.33K-$13.33M-$7.40M-$15.21M-$5.72M
    Capital expenditures$0$10.30M$319.12K$141.36K$210.19K$194.48K$2.01K$7.68K$8.06K$17.00K
    Free cash flow-$6.33M-$20.61M-$13.57M-$14.87M-$9.97M-$137.15K-$13.33M-$7.41M-$15.22M-$5.74M
    Dividends paid$87.60KN/A$2.90MN/AN/AN/A$2.54M$3.11MN/A$327.57K
    Investing cash flow-$1.91M$4.22M-$183.76K-$141.36K-$160.56K-$194.48K-$225.83K-$7.68K-$8.06K-$17.00K
    Financing cash flow$9.01M-$550.00K$2.91M$8.43M$33.76M$165.14K$5.48M$22.99M$6.44M$18.81M
    Fiscal years ended Dec 2015 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$2.14M-$1.10M-$2.27M-$2.27M-$1.80M-$1.47M-$783.59K-$5.67M$929.74K-$2.93M-$2.63M-$2.24M
    Capital expenditures$0$0$0$0$2$2$0$0$246.42K$48.41K$198.01K$244.37K
    Free cash flow-$2.14M-$1.10M-$2.27M-$2.27M-$1.80M-$1.47M-$783.59K-$5.67M$683.32K-$2.98M-$2.83M-$2.48M
    Last 12 quarters

    Frequently Asked Questions About QLGN

    What is Qualigen Therapeutics' annual revenue?

    Qualigen Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2024.

    How fast is Qualigen Therapeutics' revenue growing?

    Revenue was down 100.0% for the fiscal year ended Dec 31, 2024 compared with the year before.

    Is Qualigen Therapeutics profitable?

    No. Qualigen Therapeutics reported net income of -$6.16M for the fiscal year ended Dec 31, 2024.

    How much free cash flow does QLGN generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$6.33M minus capital expenditures of $0 produced free cash flow of -$6.33M.

    How much debt does Qualigen Therapeutics have?

    The balance sheet dated Dec 31, 2024 reported cash and equivalents of $1.17M.